Does the media favor RYTM or BCAX?

In the previous week, Bicara Therapeutics had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Bicara Therapeutics' average media sentiment score of 0.86 beat Rhythm Pharmaceuticals' score of 0.34 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCAX or MIRM?

In the previous week, Bicara Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Bicara Therapeutics' score of 0.86 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCAX or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat Lantheus' score of 0.71 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCAX or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 9 mentions for PTC Therapeutics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat PTC Therapeutics' score of 0.34 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SRRK or BCAX?

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is SRRK or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Bicara Therapeutics N/A -35.89% -33.78%

Does the media refer more to SRRK or BCAX?

In the previous week, Scholar Rock had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat Scholar Rock's score of 0.46 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bicara Therapeutics (BCAX) Competitors

$27.15 -0.61 (-2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$27.14 0.00 (-0.02%)

As of 07:34 PM Eastern

Compare

BCAX vs. RYTM, MIRM, LNTH, PTCT, and SRRK

Should you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), PTC Therapeutics (PTCT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Bicara Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Bicara Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	37.78	-$196.54M	-$3.13	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $138.29, suggesting a potential upside of 32.20%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 11.50%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Bicara Therapeutics had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Bicara Therapeutics' average media sentiment score of 0.86 beat Rhythm Pharmaceuticals' score of 0.34 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Bicara Therapeutics' return on equity of -35.89% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

Summary

Bicara Therapeutics beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Mirum Pharmaceuticals has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Mirum Pharmaceuticals	$521.31M	13.64	-$23.36M	-$13.61	N/A

Bicara Therapeutics presently has a consensus target price of $30.27, suggesting a potential upside of 11.50%. Mirum Pharmaceuticals has a consensus target price of $143.40, suggesting a potential upside of 22.96%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Bicara Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 4 mentions for Bicara Therapeutics and 3 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Bicara Therapeutics' score of 0.86 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Bicara Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Bicara Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Bicara Therapeutics compare to Lantheus?

Bicara Therapeutics (NASDAQ:BCAX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Lantheus had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat Lantheus' score of 0.71 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Lantheus	$1.54B	4.41	$233.56M	$4.15	25.16

Lantheus has a net margin of 18.05% compared to Bicara Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Lantheus	18.05%	29.32%	15.00%

Bicara Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bicara Therapeutics currently has a consensus price target of $30.27, suggesting a potential upside of 11.50%. Lantheus has a consensus price target of $110.43, suggesting a potential upside of 5.77%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Bicara Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Lantheus beats Bicara Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicara Therapeutics compare to PTC Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

PTC Therapeutics has higher revenue and earnings than Bicara Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 9 mentions for PTC Therapeutics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat PTC Therapeutics' score of 0.34 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicara Therapeutics presently has a consensus target price of $30.27, suggesting a potential upside of 11.50%. PTC Therapeutics has a consensus target price of $92.29, suggesting a potential upside of 18.30%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bicara Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Bicara Therapeutics' return on equity of -35.89% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Bicara Therapeutics has a beta of -0.81, meaning that its share price is 181% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

PTC Therapeutics beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Bicara Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

Scholar Rock presently has a consensus price target of $56.00, suggesting a potential upside of 10.54%. Bicara Therapeutics has a consensus price target of $30.27, suggesting a potential upside of 11.50%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Scholar Rock had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.86 beat Scholar Rock's score of 0.46 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Bicara Therapeutics beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-9.77	10.89	22.26	21.51
Price / Sales	N/A	300.39	517.96	91.07
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	3.70	7.92	10.66	6.14
Net Income	-$137.95M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.55%	-1.27%	-1.51%	-1.72%
1 Month Performance	16.87%	2.56%	1.11%	-1.44%
1 Year Performance	148.40%	42.49%	23.77%	16.97%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	2.0328 of 5 stars	$27.15 -2.2%	$30.27 +11.5%	+154.0%	$1.82B	N/A	N/A	32
RYTM Rhythm Pharmaceuticals	2.7247 of 5 stars	$109.96 +2.3%	$138.29 +25.8%	+19.5%	$7.37B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	3.2301 of 5 stars	$120.89 +1.6%	$143.40 +18.6%	+128.9%	$7.26B	$521.31M	N/A	140	Positive News
LNTH Lantheus	2.4244 of 5 stars	$102.37 -2.9%	$108.29 +5.8%	+53.3%	$6.86B	$1.55B	24.67	1,193
PTCT PTC Therapeutics	3.3904 of 5 stars	$78.06 -4.0%	$91.57 +17.3%	+65.0%	$6.75B	$1.73B	N/A	1,410	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. RYTM, MIRM, LNTH, PTCT, and SRRK

How does Bicara Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Bicara Therapeutics compare to Lantheus?

Summary

How does Bicara Therapeutics compare to PTC Therapeutics?

Summary

How does Bicara Therapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. RYTM, MIRM, LNTH, PTCT, and SRRK

How does Bicara Therapeutics compare to Rhythm Pharmaceuticals?

Which has stronger valuation and earnings, RYTM or BCAX?

Do analysts rate RYTM or BCAX?

Does the media favor RYTM or BCAX?

Is RYTM or BCAX more profitable?

Which has more volatility and risk, RYTM or BCAX?

Summary

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Which has stronger valuation and earnings, BCAX or MIRM?

Do analysts prefer BCAX or MIRM?

Does the media refer more to BCAX or MIRM?

Which has more volatility and risk, BCAX or MIRM?

Is BCAX or MIRM more profitable?

Summary

How does Bicara Therapeutics compare to Lantheus?

Does the media favor BCAX or LNTH?

Which has better valuation and earnings, BCAX or LNTH?

Is BCAX or LNTH more profitable?

Which has more risk & volatility, BCAX or LNTH?

Do insiders & institutionals have more ownership in BCAX or LNTH?

Do analysts recommend BCAX or LNTH?

Summary

How does Bicara Therapeutics compare to PTC Therapeutics?

Which has higher earnings & valuation, BCAX or PTCT?

Does the media refer more to BCAX or PTCT?

Do analysts recommend BCAX or PTCT?

Is BCAX or PTCT more profitable?

Which has more risk and volatility, BCAX or PTCT?

Summary

How does Bicara Therapeutics compare to Scholar Rock?

Is SRRK or BCAX more profitable?

Which has more risk & volatility, SRRK or BCAX?

Do analysts rate SRRK or BCAX?

Which has stronger valuation and earnings, SRRK or BCAX?

Does the media refer more to SRRK or BCAX?

Do institutionals & insiders have more ownership in SRRK or BCAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools